今日观察！A Wave of "Kete Valuation" Sweeps Through the Market: 50 Stocks Poised for Strong Growth

A Wave of "Kete Valuation" Sweeps Through the Market: 50 Stocks Poised for Strong Growth

Shanghai, China - June 17, 2024 - A recent surge in investor sentiment towards growth stocks, particularly in the healthcare and technology sectors, has been dubbed the "Kete Valuation" phenomenon, named after the Chinese pharmaceutical company C-Bridge (6160.HK). This trend is reminiscent of the "CATL Valuation" rally that occurred in 2021, driven by the strong performance of Contemporary Amperex Technology Co., Ltd. (300015.SZ).

The "Kete Valuation" is characterized by a sharp increase in the share prices of companies with promising growth prospects, often defying broader market trends. This is evident in the recent performance of 50 stocks identified by analysts as having significant growth potential. These stocks, spanning various industries including healthcare, technology, and consumer goods, have exhibited remarkable resilience amidst recent market volatility.

Factors Driving the "Kete Valuation"

Several factors are contributing to the "Kete Valuation" trend. Firstly, investors are increasingly seeking out companies that can deliver sustainable growth, particularly in the face of global economic uncertainties. Secondly, the easing of monetary policy in major economies is providing a supportive backdrop for riskier assets like growth stocks. Additionally, advancements in technology and innovation are creating new opportunities for companies in various sectors, fueling investor optimism.

Key Beneficiaries of the "Kete Valuation"

Among the 50 stocks identified as potential beneficiaries of the "Kete Valuation," C-Bridge (6160.HK) stands out as a frontrunner. The company's innovative cancer therapies and strong pipeline of new drugs have attracted significant investor interest. Other notable stocks include:

• Ascletis Pharma (1672.HK): A clinical-stage biopharmaceutical company developing novel therapies for cancer and viral diseases.

• Aier Eye Hospital Group (300015.SZ): A leading provider of comprehensive eye care services in China.

• Xiaomi Corporation (1810.HK): A global technology company known for its smartphones, smart home devices, and internet services.

Investment Implications

The "Kete Valuation" presents an opportunity for investors to capitalize on the growth potential of select companies. However, careful due diligence is crucial, as not all growth stocks are created equal. Investors should thoroughly evaluate a company's financial health, competitive landscape, and long-term growth prospects before making investment decisions.

The "Kete Valuation" highlights the evolving dynamics of the Chinese stock market, where investors are increasingly discerning and seeking out companies with genuine growth potential. This trend is likely to continue as China's economy transitions towards a more innovation-driven and knowledge-based model.

美联储降息预期或成明日黄花？三菱日联预计美元将迎来下跌周期

东京，2024年6月14日 - 全球知名金融机构三菱日联近日发布最新报告，指出美联储此前预测的2024年三次降息预期可能已经过时，美元在今年下半年可能转入下跌周期。

该报告指出，美联储主席鲍威尔在6月议息会议后的讲话中释放出鹰派信号，暗示美联储可能会维持高利率政策更长时间以遏制通胀。这一鹰派立场与美联储此前公布的点阵图预测存在一定出入，也令市场对美联储未来降息步伐产生疑虑。

三菱日联外汇分析师Lee Hardman表示，尽管美联储将2024年降息次数下调至一次，但5月公布的美国疲弱通胀数据表明，今年内仍有可能出现多次降息。他指出，鲍威尔的鹰派言论可能只是为了安抚市场预期，并不能完全反映美联储的真实政策意图。

Hardman认为，美联储如果坚持激进加息政策，可能会导致美国经济陷入衰退，进而迫使美联储转向降息。此外，全球主要经济体央行近期纷纷释放宽松政策信号，也为美联储降息提供了外部空间。

基于上述分析，三菱日联预计美元在今年下半年将承压下行。Hardman建议投资者关注美国经济数据和美联储政策变化，并适时调整投资策略。

该报告的发布引发了市场广泛关注，也为全球金融市场增添了一份新的不确定性。 投资者应密切关注美联储的政策动向和全球经济形势，审慎评估投资风险。